1	Comparison	Comparison	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	laboratory	laboratory	B-NP	NN	O	4	NMOD
4	costs	cost	I-NP	NNS	O	2	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	rapid	rapid	B-NP	JJ	O	8	NMOD
7	molecular	molecular	I-NP	JJ	O	8	NMOD
8	tests	test	I-NP	NNS	O	11	NMOD
9	and	and	O	CC	O	11	NMOD
10	conventional	conventional	B-NP	JJ	O	11	NMOD
11	diagnostics	diagnostic	I-NP	NNS	O	5	PMOD
12	for	for	B-PP	IN	O	1	NMOD
13	detection	detection	B-NP	NN	O	12	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	tuberculosis	tuberculosis	B-NP	NN	O	18	NMOD
16	and	and	O	CC	O	18	NMOD
17	drug-resistant	drug-resistant	B-NP	JJ	O	18	NMOD
18	tuberculosis	tuberculosis	I-NP	NN	O	14	PMOD
19	in	in	B-PP	IN	O	13	NMOD
20	South	South	B-NP	NNP	O	21	NMOD
21	Africa	Africa	I-NP	NNP	O	19	PMOD
22	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	4	NMOD
2	World	World	I-NP	NNP	O	4	NMOD
3	Health	Health	I-NP	NNP	O	4	NMOD
4	Organization	Organization	I-NP	NNP	O	5	SUB
5	has	have	B-VP	VBZ	O	0	ROOT
6	endorsed	endorse	I-VP	VBN	O	5	VC
7	the	the	B-NP	DT	O	8	NMOD
8	use	use	I-NP	NN	O	6	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	molecular	molecular	B-NP	JJ	O	11	NMOD
11	methods	method	I-NP	NNS	O	9	PMOD
12	for	for	B-PP	IN	O	11	NMOD
13	the	the	B-NP	DT	O	14	NMOD
14	detection	detection	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	TB	TB	B-NP	NN	B-protein	19	NMOD
17	and	and	O	CC	O	19	NMOD
18	drug-resistant	drug-resistant	B-NP	JJ	O	19	NMOD
19	TB	TB	I-NP	NN	O	15	PMOD
20	as	as	B-PP	IN	O	6	VMOD
21	a	a	B-NP	DT	O	23	NMOD
22	rapid	rapid	I-NP	JJ	O	23	NMOD
23	alternative	alternative	I-NP	NN	O	20	PMOD
24	to	to	B-PP	TO	O	23	NMOD
25	culture-based	culture-based	B-NP	JJ	O	26	NMOD
26	systems	system	I-NP	NNS	O	24	PMOD
27	.	.	O	.	O	5	P

1	In	In	B-PP	IN	O	13	VMOD
2	South	South	B-NP	NNP	O	3	NMOD
3	Africa	Africa	I-NP	NNP	O	1	PMOD
4	,	,	O	,	O	13	P
5	the	the	B-NP	DT	O	8	NMOD
6	Xpert	Xpert	I-NP	NNP	O	8	NMOD
7	MTB/Rif	MTB/Rif	I-NP	NN	O	8	NMOD
8	assay	assay	I-NP	NN	O	12	NMOD
9	and	and	O	CC	O	12	NMOD
10	the	the	B-NP	DT	O	12	NMOD
11	GenoType	GenoType	I-NP	NN	O	12	NMOD
12	MTBDRplus	MTBDRplus	I-NP	NN	O	13	SUB
13	have	have	B-VP	VBP	O	29	VMOD
14	been	be	I-VP	VBN	O	13	VC
15	implemented	implement	I-VP	VBN	O	14	VC
16	into	into	B-PP	IN	O	15	VMOD
17	reference	reference	B-NP	NN	O	18	NMOD
18	laboratories	laboratory	I-NP	NNS	O	16	PMOD
19	for	for	B-PP	IN	O	18	NMOD
20	diagnosis	diagnosis	B-NP	NN	O	19	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	TB	TB	B-NP	NN	B-protein	24	NMOD
23	and	and	I-NP	CC	O	24	NMOD
24	drug-resistance	drug-resistance	I-NP	NN	O	21	PMOD
25	,	,	O	,	O	29	P
26	but	but	O	CC	O	29	VMOD
27	their	their	B-NP	PRP$	O	28	NMOD
28	costs	cost	I-NP	NNS	O	29	SUB
29	have	have	B-VP	VBP	O	0	ROOT
30	not	not	I-VP	RB	O	29	VMOD
31	been	be	I-VP	VBN	O	29	VC
32	fully	fully	B-ADJP	RB	O	31	VMOD
33	elucidated	elucidate	I-ADJP	VBN	O	31	VC
34	.	.	O	.	O	29	P

1	We	We	B-NP	PRP	O	2	SUB
2	conducted	conduct	B-VP	VBD	O	0	ROOT
3	a	a	B-NP	DT	O	8	NMOD
4	detailed	detailed	I-NP	JJ	O	8	NMOD
5	reference	reference	I-NP	NN	O	8	NMOD
6	laboratory	laboratory	I-NP	NN	O	8	NMOD
7	cost	cost	I-NP	NN	O	8	NMOD
8	analysis	analysis	I-NP	NN	O	2	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	new	new	B-NP	JJ	O	13	NMOD
11	rapid	rapid	I-NP	JJ	O	13	NMOD
12	molecular	molecular	I-NP	JJ	O	13	NMOD
13	assays	assay	I-NP	NNS	O	9	PMOD
14	(	(	O	(	O	18	DEP
15	Xpert	Xpert	B-NP	NN	O	17	NMOD
16	and	and	O	CC	O	17	NMOD
17	MTBDRplus	MTBDRplus	B-NP	NN	O	18	DEP
18	)	)	O	)	O	13	NMOD
19	for	for	B-PP	IN	O	13	NMOD
20	tuberculosis	tuberculosis	B-NP	NN	O	21	NMOD
21	testing	testing	I-NP	NN	O	24	NMOD
22	and	and	O	CC	O	24	NMOD
23	drug-resistance	drug-resistance	B-NP	NN	O	24	NMOD
24	testing	testing	I-NP	NN	O	19	PMOD
25	in	in	B-PP	IN	O	24	NMOD
26	South	South	B-NP	NNP	O	27	NMOD
27	Africa	Africa	I-NP	NNP	O	25	PMOD
28	,	,	O	,	O	2	P
29	and	and	O	CC	O	2	VMOD
30	compared	compare	B-PP	VBN	O	2	VMOD
31	with	with	B-PP	IN	O	30	PMOD
32	the	the	B-NP	DT	O	33	NMOD
33	costs	cost	I-NP	NNS	O	31	PMOD
34	of	of	B-PP	IN	O	33	NMOD
35	conventional	conventional	B-NP	JJ	O	36	NMOD
36	approaches	approach	I-NP	NNS	O	34	PMOD
37	involving	involve	B-VP	VBG	O	36	NMOD
38	sputum	sputum	B-NP	NN	O	39	NMOD
39	microscopy	microscopy	I-NP	NN	O	49	NMOD
40	,	,	O	,	O	49	P
41	liquid	liquid	B-NP	JJ	O	43	NMOD
42	mycobacterial	mycobacterial	I-NP	JJ	O	43	NMOD
43	culture	culture	I-NP	NN	O	49	NMOD
44	,	,	O	,	O	49	P
45	and	and	O	CC	O	49	NMOD
46	phenotypic	phenotypic	B-NP	JJ	O	49	NMOD
47	drug	drug	I-NP	NN	O	49	NMOD
48	sensitivity	sensitivity	I-NP	NN	O	49	NMOD
49	testing	testing	I-NP	NN	O	37	OBJ
50	.	.	O	.	O	2	P

1	From	From	B-PP	IN	O	8	VMOD
2	a	a	B-NP	DT	O	4	NMOD
3	laboratory	laboratory	I-NP	NN	O	4	NMOD
4	perspective	perspective	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	8	P
6	Xpert	Xpert	B-NP	NNP	O	7	NMOD
7	MTB/RIF	MTB/RIF	I-NP	NNP	O	8	SUB
8	cost	cost	B-VP	VBD	O	0	ROOT
9	$	$	B-NP	$	O	8	VMOD
10	14.93/sample	14.93/sample	I-NP	JJ	O	16	NMOD
11	and	and	O	CC	O	16	NMOD
12	the	the	B-NP	DT	O	16	NMOD
13	MTBDRplus	MTBDRplus	I-NP	NN	O	16	NMOD
14	line	line	I-NP	NN	O	16	NMOD
15	probe	probe	I-NP	NN	O	16	NMOD
16	assay	assay	I-NP	NN	O	17	SUB
17	cost	cost	B-VP	VBD	O	9	SBAR
18	$	$	B-NP	$	O	17	VMOD
19	23.46/sample	23.46/sample	I-NP	JJ	O	18	OBJ
20	,	,	O	,	O	19	P
21	compared	compare	B-PP	VBN	O	19	NMOD
22	to	to	B-PP	TO	O	21	VMOD
23	$	$	B-NP	$	O	22	PMOD
24	16.88/sample	16.88/sample	I-NP	CD	O	23	NMOD
25	using	use	B-VP	VBG	O	21	VMOD
26	conventional	conventional	B-NP	JJ	O	30	NMOD
27	automated	automate	I-NP	VBN	O	30	NMOD
28	liquid	liquid	I-NP	JJ	O	30	NMOD
29	culture-based	culture-based	I-NP	JJ	O	30	NMOD
30	methods	method	I-NP	NNS	O	25	OBJ
31	.	.	O	.	O	8	P

1	Laboratory	Laboratory	B-NP	NN	O	2	NMOD
2	costs	cost	I-NP	NNS	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	Xpert	Xpert	B-NP	NNP	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	MTBDRplus	MTBDRplus	I-NP	NNP	O	3	PMOD
7	were	be	B-VP	VBD	O	0	ROOT
8	most	most	I-VP	RBS	O	7	VMOD
9	influenced	influence	I-VP	VBN	O	7	VC
10	by	by	B-PP	IN	O	9	VMOD
11	cost	cost	B-NP	NN	O	10	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	consumables	consumable	B-NP	NNS	O	12	PMOD
14	(	(	O	(	O	17	DEP
15	60-80	60-80	B-NP	CD	O	16	NMOD
16	%	%	I-NP	NN	O	17	DEP
17	)	)	O	)	O	13	NMOD
18	.	.	O	.	O	7	P

1	At	At	B-PP	IN	O	11	VMOD
2	current	current	B-NP	JJ	O	5	NMOD
3	public	public	I-NP	JJ	O	5	NMOD
4	sector	sector	I-NP	NN	O	5	NMOD
5	pricing	pricing	I-NP	NN	O	1	PMOD
6	,	,	O	,	O	11	P
7	Xpert	Xpert	B-NP	NNP	O	8	NMOD
8	MTB/RIF	MTB/RIF	I-NP	NNP	O	10	NMOD
9	and	and	O	CC	O	10	NMOD
10	MTBDRplus	MTBDRplus	B-NP	NNP	O	11	SUB
11	are	be	B-VP	VBP	O	0	ROOT
12	comparable	comparable	B-ADJP	JJ	O	11	PRD
13	in	in	B-PP	IN	O	12	AMOD
14	cost	cost	B-NP	NN	O	22	NMOD
15	to	to	B-PP	TO	O	14	NMOD
16	mycobacterial	mycobacterial	B-NP	JJ	B-cell_line	17	NMOD
17	culture	culture	I-NP	NN	I-cell_line	15	PMOD
18	and	and	O	CC	O	22	NMOD
19	conventional	conventional	B-NP	JJ	O	22	NMOD
20	drug	drug	I-NP	NN	O	22	NMOD
21	sensitivity	sensitivity	I-NP	NN	O	22	NMOD
22	testing	testing	I-NP	NN	O	13	PMOD
23	.	.	O	.	O	11	P

1	Overall	Overall	B-ADVP	RB	O	5	VMOD
2	,	,	O	,	O	5	P
3	reference	reference	B-NP	NN	O	4	NMOD
4	laboratories	laboratory	I-NP	NNS	O	5	SUB
5	must	must	B-VP	MD	O	0	ROOT
6	balance	balance	I-VP	VB	O	5	VC
7	costs	cost	B-NP	NNS	O	6	OBJ
8	with	with	B-PP	IN	O	7	NMOD
9	performance	performance	B-NP	NN	O	10	NMOD
10	characteristics	characteristic	I-NP	NNS	O	13	NMOD
11	and	and	O	CC	O	13	NMOD
12	the	the	B-NP	DT	O	13	NMOD
13	need	need	I-NP	NN	O	8	PMOD
14	for	for	B-PP	IN	O	13	NMOD
15	rapid	rapid	B-NP	JJ	O	16	NMOD
16	results	result	I-NP	NNS	O	14	PMOD
17	.	.	O	.	O	5	P

